Spannabis B2B
News
Cannabis business news.
- Curaleaf’s hostile bid for Aurora: what’s at stake in Europe
Aurora again rejects Curaleaf’s hostile bid, open until 4 December. The numbers, the arguments and what it means for European medical cannabis. - Medical cannabis in Spanish hospitals: dispensing begins
Medical cannabis reaches Spanish hospital pharmacies a year after Royal Decree 903/2025. What it means for growers, labs and pharma distributors. - Medical cannabis in France: the final decree draws near
France awaits a Conseil d’État ruling on its reimbursement decree to complete its medical cannabis framework. Which products qualify and when the market opens. - EU-GMP quality control: Tilray brings batch testing in-house
Portugal clears Tilray to test flower batches at its EU-GMP site in Cantanhede. What it means for costs, lead times and European medical cannabis supply. - Bedrocan bankruptcy: Dutch medical cannabis left without a grower
Bedrocan, the only licensed medical cannabis grower in the Netherlands, is bankrupt. The BMC will import in 2027: what it means for EU-GMP producers. - Hemp flower in Italy: Constitutional Court delays to 2027
Italy’s Constitutional Court moves its review of the Article 18 hemp flower ban to 9 February 2027. What changes, and what doesn’t, for hemp businesses. - Plant-derived dronabinol: Irish EU-GMP API reaches the UK
Dunbar Pharma brings the UK’s first plant-derived dronabinol oral spray. What the EU-GMP API plus Specials model means for cannabis businesses. - Germany eases medical cannabis reimbursement rules
Germany’s coalition amends the mandatory six-month trial with licensed cannabis medicines. Flower stays out of reimbursement. What it means for the industry. - Netherlands ends medical cannabis exports via the OMC
The OMC stops exporting, Bedrocan enters suspension of payments and Denmark fears a supply gap in 2027. What it means for Europe’s cannabis trade.